Imperagen is pleased to announce the appointment of Dr. Rob Wilson as its new Chief Executive Officer
A seasoned biotech executive, Rob brings over 20 years of international experience in biotechnology commercialization to the role.
His appointment marks a pivotal moment as Imperagen moves into its next phase of growth—expanding the use of its platform in both third-party collaborations and internal product development.
Under Rob’s leadership, the company will build on its successful first phase, during which its Digital Enzyme Evolution™ platform delivered commercially optimized enzymes, and will now focus on scaling and product innovation across sectors including pharmaceuticals, life sciences, and industrial biotechnology.
Rob is an international biotech executive with over two decades of experience in gene synthesis and enzyme optimization. He will lead the company into its next growth phase using the platform in third party projects as well as in-house product development, building on Imperagen’s first phase of technology development that has already led to optimized enzymes for commercial use.
“I am very happy to be joining the Imperagen team, as CEO, at an exciting time in the Company’s journey. Our technology platform is unique, and we are well positioned to grow by delivering new products in sectors such as pharmaceuticals, life science, and industrial biotechnology. I am confident that the deep integration of AI technologies, modern robotics and a core focus on product development will be a winning combination that will deliver significant value for customers and investors.”
– Dr Rob Wilson, Chief Executive Officer
Dr. Peter Seufer-Wasserthal, Non-executive Chairman of the Board, added:
“Rob is a visionary leader with a proven capability of commercializing technology and products in the enzyme and gene synthesis market. Rob’s experience in technology operations and business development in the biotech, pharma and consumer markets uniquely positions him to oversee the implementation of our strategic initiatives as we expand our platform and start developing our own products. On behalf of the Board of Directors, I would like to thank Andrew Almond for his stewardship as the first CEO of Imperagen, and we look forward to his continued leadership in the newly created position as Chief Information Officer.”
With this leadership transition, Imperagen is well positioned to scale its operations and accelerate innovation at the forefront of enzyme engineering.
